Brian Dicarlo, MD
Hematology & Oncology · San Luis Obispo, CANPI 1982728796
Payments from drug & device makers
Across 122 payments — averaging $1290.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$123K
- Genentech, Inc.$11K
- Pfizer$6K
- AstraZeneca$5K
- Halozyme Inc$5K
- Novartis$3K
- plus $5K from 24 others
Across 2 payments — averaging $1104.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Food & beverage$1,87455%
- Education$41112%
- Other$1,09832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 28 | $123,137 |
| Genentech, Inc. | 4 | $10,632 |
| Pfizer | 24 | $6,052 |
| AstraZeneca | 4 | $5,139 |
| Halozyme Inc | 2 | $4,556 |
| Novartis | 16 | $3,183 |
| Puma Biotechnology, Inc. | 1 | $2,094 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,000 |
| Lilly USA, LLC | 2 | $249 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $185 |
| Gilead(2 entities) | 3 | $149 |
| Merck | 4 | $142 |
| AbbVie | 2 | $125 |
| Genmab U.S., Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $123 |
| Bristol Myers Squibb | 2 | $53 |
| Secura Bio, Inc. | 2 | $50 |
| Abbott | 1 | $46 |
| Johnson & Johnson | 2 | $45 |
| Medtronic | 2 | $43 |
| Tolmar Pharmaceuticals, Inc. | 1 | $42 |
| Array Biopharma Inc | 2 | $35 |
| EMD Serono, Inc. | 2 | $33 |
| Exelixis Inc. | 2 | $32 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Sanofi | 1 | $22 |
| Genentech USA, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Tesaro, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,394 in reported general payments places this provider in the 75th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 45 | $841,644 |
| JakafiRuxolitinib Phosphate | 25 | $719,824 |
| RevlimidLenalidomide | 32 | $664,855 |
| TagrissoOsimertinib Mesylate | 34 | $547,566 |
| CabometyxCabozantinib S-Malate | 17 | $477,927 |
| ImbruvicaIbrutinib | 28 | $449,561 |
| PomalystPomalidomide | 19 | $435,601 |
| KisqaliRibociclib Succinate | 26 | $413,199 |
| XtandiEnzalutamide | 31 | $412,909 |
| NubeqaDarolutamide | 23 | $310,479 |
| BrukinsaZanubrutinib | 21 | $308,498 |
| TabrectaCapmatinib Hydrochloride | 12 | $268,793 |
| OrserduElacestrant Hcl | 11 | $254,874 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $178,721 |
| TafinlarDabrafenib Mesylate | 11 | $123,458 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tabrecta, Mekinist, Tafinlar, Promacta | $3,183 | $1,068,72072 claims |
| Bristol Myers SquibbRevlimid | $53 | $664,85532 claims |
| AstraZenecaTagrisso | $5,139 | $547,56634 claims |
| Exelixis Inc.Cabometyx | $32 | $477,92717 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $185 | $449,56128 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $123,137 | $435,60119 claims |
| PfizerEliquis | $6,052 | $22,89335 claims |
| Lilly USA, LLCOlanzapine | $249 | $30220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in San Luis Obispo
- Alain AlgaziSan Francisco$119.2M
- David BerzLos Angeles$43.3M
- Jonathan GoldmanSanta Monica$35.7M
- Omid HamidSanta Monica$23.7M
- Nicholas McAndrewLos Angeles$22.9M
- Aditya BardiaSanta Monica$22.1M
- Joseph TuscanoSacramento$20.4M
- Zev WainbergSanta Monica$19.3M
- Caitlin CostelloSan Diego$16.9M
- Rana McKaySan Diego$15.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.